Why did Metropolis Healthcare (METROPOLIS) stock move recently?

On 8/5/2026, Metropolis Healthcare moved -3.3% — Metropolis Healthcare shares fell ~3% alongside a sharp broader market sell-off (Sensex down over 1,600 points), despite positive Q1 results showing ~26% YoY net profit growth; no company-specific negative catalyst identified. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Metropolis Healthcare (METROPOLIS) overvalued or fairly valued?

MarketChacha shows Metropolis Healthcare's valuation in context — a forward P/E of about 36.4, a price-to-book of about 7.8 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Metropolis Healthcare's revenue?

Metropolis Healthcare reported revenue of ₹1,365 Cr for FY2026, with net profit of ₹157 Cr, per official filings.

What is the share price of Metropolis Healthcare (METROPOLIS)?

Metropolis Healthcare last traded at ₹566.25 (-1.1% on the day), as of 8/11/2026 — a delayed quote shown for education, not investment advice.

Metropolis Healthcare

METROPOLIS · NSE · Healthcare · India

Snapshot

TickerMETROPOLIS

ExchangeNSE

SectorHealthcare

IndustryDiagnostics & Research

CountryIndia

Employees4,484

HeadquartersMumbai, India

Websitewww.metropolisindia.com

Filings tracked7

About Metropolis Healthcare

Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India and internationally. The company offers routine and specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; clinical trial research, hospital lab management, and home collection services; radiology services, including X-ray, sonography and ECG; and next-generation sequencing services. It also provides diagnostic services for oncology, chronic and infectious diseases, gastroenterology, neurology, nephrology, and women and child health, as well as various health checkup and laboratory services. The company serves a range of customers, including direct-to-consumer diagnostics through patient service centers, mobile app, website, and home collection; partnerships with standalone labs, hospital chains, and diagnostic networks; and institutional clients, such as corporates, government bodies, and hospital lab management services. Metropolis Healthcare Limited was founded in 1980 and is headquartered in Mumbai, India.

Who owns it

Promoters48.9%
Institutions44.9%
Public & other6.3%

57 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend12.4% → 11.5%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev 9% · PAT 7%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹467 Cr · EPS 2.80

Est. earnings growth +21.4%

Next fiscal year

Rev ₹2,187 Cr · EPS 15.56

Est. earnings growth +25.8%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 5

Revenue (FY2026)

₹1,646 Cr

Net margin

11.5%

Revenue CAGR (3y)

+12.8%

Profit CAGR (3y)

+10.0%

Net profit (FY2026)

₹190 Cr

Ask MarketChacha about METROPOLIS

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Aug 5, 2026
Metropolis Healthcare shares fell ~3% alongside a sharp broader market sell-off (Sensex down over 1,600 points), despite positive Q1 results showing ~26% YoY net profit growth; no company-specific negative catalyst identified.
source 1 ↗source 2 ↗· confidence: medium

Daily moves with the verified reason behind them. Education only — not investment advice.

On MarketChacha

Posts about METROPOLIS

c/india-daily · 8/3/2026▲ 0

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹1,646 Cr	₹190 Cr	11.5%
FY2025	₹1,331 Cr	₹145 Cr	10.9%
FY2024	₹1,208 Cr	₹128 Cr	10.6%
FY2023	₹1,148 Cr	₹143 Cr	12.4%

Quarterly

Period	Revenue	Net profit	Net margin
Q1 FY27	₹450 Cr	₹57 Cr	12.6%
Q4 FY26	₹425 Cr	₹51 Cr	12.0%
Q3 FY26	₹406 Cr	₹41 Cr	10.2%
Q2 FY26	₹429 Cr	₹53 Cr	12.3%
Q1 FY26	₹386 Cr	₹45 Cr	11.7%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Grant Of Stock Benefits
Grant of Stock Benefits
BSE8/4/2026
Allotment of ESOP / ESPS
Allotment of 18,700 equity shares under the Metropolis-Restrictive Stock Unit Plan, 2020
BSE8/4/2026
Board Meeting Intimation for Considering And Approving The Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended June 30, 2026
Metropolis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2026 ,inter alia, to consider and approve the un-audited standalone ....
BSE7/28/2026material
Letter To Shareholders Containing Weblink Of Annual Report For The Financial Year 2025-26 And 26Th Annual General Meeting
Letter to Shareholders containing weblink of Annual Report for the financial year 2025-26 and 26th Annual General Meeting
BSE7/27/2026
Business Responsibility and Sustainability Reporting (BRSR)
Business Responsibility and Sustainability Report for the financial year 2025-26
BSE7/27/2026
Notice Of The 26Th Annual General Meeting For The Financial Year 2025-26
Notice of the 26th Annual General Meeting for the financial year 2025-26 to be held on August 18, 2026
BSE7/27/2026material
Reg. 34 (1) Annual Report.
Annual Report for the financial year 2025-26
BSE7/27/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.